Navigation Links
Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
Date:7/11/2012

STATES.

Silence Therapeutics plc

("Silence" or the "Company")

Subscription and Open Offer of New Ordinary Shares

The Board of Silence is pleased to announce a Fundraising of up to £5.7 million (before expenses) through the issue of up to 840,000,000 New Ordinary Shares by way of a Subscription at 0.5 pence per Ordinary Share to certain investors and Directors and up to a further 100,019,847 New Ordinary Shares to be issued through an Open Offer at 0.5 pence per New Ordinary Share and the issue of a Convertible Loan Note of £1 million.  The Issue Price represents a discount of approximately 44 per cent. to the price of 0.89 pence per share, being the Closing Price of the Company's Ordinary Shares on 11 July 2012.  The Company also announces that it has entered into a £10 million Equity Finance Facility ("EFF"), conditional upon Admission, with Darwin Strategic Limited, a subsidiary of Alphagen Volantis Fund ("Henderson") part of the fund management group Henderson Global Investors ("Darwin").

The Fundraising is conditional, inter alia, upon the passing by Shareholders of certain Resolutions at the General Meeting (and is subject to the effect of the Share Capital Reorganisation).

The total amount that the Company could raise under the Fundraising is £5.7 million (before expenses), assuming all the Open Offer Entitlements are taken up.  The Subscription, the Open Offer and the Convertible Loan Note are not underwritten.

The circular (the "Circular") relating to the Subscription and Open Offer will be posted to shareholders today.  The Circular contains a notice of general meeting to approve, inter alia, the Subscription and Open Offer which will be held at the offices of Covington & Burling LLP, 265 Strand, London, WC2R 1BH at 10.00 a.m. on 31 July 2012.

The Circular will soon be available to view on the Company's website (
'/>"/>

SOURCE Silence Therapeutics Plc
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
2. Silence Therapeutics Announces Board Changes and Appointment of New Chief Executive Officer
3. Silence Therapeutics Additional Listing
4. Silence Therapeutics Announces Positive Response by USPTO that Affirms Validity of Four Foundational RNAi Patents
5. Silence Therapeutics Announces Positive Outcome From Oral Hearing at the European Patent Office
6. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
7. Bio-Innovator Saneron CCEL Therapeutics Supports Cryo-Cell International Leadership and Board of Directors in Proxy Contest
8. Global Neuroendocrine Carcinoma Therapeutics Market To Reach $475m By 2019 - Report
9. United Therapeutics Announces Additional $100 Million Share Repurchase Program
10. Healthpoint Biotherapeutics To Create State-of-the-Art Cell Sciences Manufacturing Facility
11. ResearchMoz: Bone Metabolism Therapeutics Market to 2018 - Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, Hectorol and Sensipar- Market Research Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... December 23, 2014 Nashville Fertility Center ... elected treasurer for the American Society for Reproductive Medicine ... and research in reproductive medicine. In his new ... on the executive board and will have a voice ... Hill has actively supported ASRM since 1984 when he ...
(Date:12/24/2014)... Dec. 23, 2014 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that investors including Oracle ... Fund LLC and several Vermillion directors have agreed ... of Vermillion,s common stock and warrants to purchase ... private placement.  Under the terms ...
(Date:12/24/2014)... PARIS and NEW YORK ... data from its open-label pilot study of mazindol in ... Design, Development and Therapy in December 2014 . ... of mazindol in children with attention deficit/hyperactivity disorder" ( ... 2014 Dec 1;8:2321-2332. eCollection 2014 ) ...
(Date:12/22/2014)... Dec. 22, 2014  Alternative Energy & Environmental ... has signed a letter of intent to acquire ... and patented a nanotechnology-based development platform used to ... enable rapid on-site collection and testing to identify ... issues in an immediate, non-invasive and cost-effective manner. ...
Breaking Biology Technology:Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 2Nashville Fertility Center Announces Dr. George A. Hill Selected to Serve as ASRM Treasurer for 2014-15 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 2Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 3Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 4Vermillion Announces Equity Financing of up to $18.9 Million; Suspends ATM Program 5Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 2Redefining ADHD: A New Approach & A Shift of Paradigm in ADHD Therapeutics 3ALNE Announces Intention To Acquire BioTechPharma 2
... Data ... ... Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn ... of Histogen,s HSC human hair regrowth product for the first time at the International ...
... , , , ... a private biotechnology company discovering and developing innovative treatments for ... the department of physiology at the University of California, San ... has joined Solace,s scientific advisory board. , , ...
... SAN DIEGO, July 24 Orexigen Therapeutics, Inc. (Nasdaq: ... their overallotment option to purchase an additional 1,500,000 shares of ... offering that priced on July 23, 2009. Including the ... public offering price of $7.50 per share, resulting in expected ...
Cached Biology Technology:Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting 2Histogen Hair Regrowth Clinical Trial Presented at ISHRS Annual Meeting 3Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board 2Solace Pharmaceuticals Appoints Professor David Julius, Renowned Pain Physiologist, to Scientific Advisory Board 3Orexigen(R) Therapeutics Announces Full Exercise of Overallotment Option by Underwriters 2
(Date:12/24/2014)... YORK , Dec. 23, 2014  Since its launch ... helped thousands of people to eliminate the pain of ... the antiquated system with their own biometrics fused to ... remember usernames and passwords, Hoyos Labs , the ... announced today that it is offering the app for ...
(Date:12/22/2014)... -- NXT-ID, Inc. (NASDAQ: NXTD and NXTDW) ... on the growing mobile commerce market, announces it has ... Robbins for the 2015 International CES debut of ... Apollo Robbins will be at the NXT-ID booth ... of his famous theft techniques to visiting media and ...
(Date:12/22/2014)... DUBLIN , Dec. 22, 2014 /PRNewswire/ ... ) has announced the addition of the ... report to their offering. ... This insight provides an overview of the ... Watermarking aims to control and monitor piracy ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4The Global Watermarking and Fingerprinting Markets 2
... 28, 2008The inaugural 2008 American Society for Microbiology ... being presented to Mary Ann Moran, Distinguished Research ... Athens. This award honors the late David C. ... approach and for being a dedicated and inspiring ...
... for Microbiology (ASM) Merck Irving S. Sigal Memorial Award ... Genetics and Microbiology, University of Texas at Austin. Sponsored ... Memorial Award is presented in memory of Irving S. ... therapies to treat HIV/AIDS, to recognize excellence in basic ...
... release is available in French . Montreal, ... to infection with HIV, the virus that causes AIDS. The ... the Research Institute of the McGill University Health Centre (MUHC) ... were published on July 16 in the journal AIDS ...
Cached Biology News:American Society for Microbiology honors Mary Ann Moran 2Genetic cause of innate resistance to HIV/AIDS 2
Control primers and template for 5kb and 15 kb products....
The Lambda Control Kit contains lambda DNA and two 25mer primers, which can be used to amplify a 500bp fragment. The lambda DNA is purified by CsCl gradient centrifugation and organic extraction foll...
... derivative of Taq DNA polymerase. It is ... polymerase. Expressed from a gene construct in ... the 5'-3' exonuclease domain of the DNA ... active and even more heat-stable DNA polymerase ...
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
Biology Products: